Knockdown of PI3K had the same effect with the dual inhibition of EGFR and IGF-1R to reduce the expression of the phosphorylated downstream molecule p-AKT in the signaling pathway, indicating that PI3K could be regarded as a potential drug target for TKI-resistant NSCLC treatment. Here, EGFR is linked to non-small cell lung carcinoma.